Derived from human induced pluripotent stem (iPS) cells, CDI’s iCell® Cardiac Progenitor Cells provide a robust, reproducible, and relevant source of cells to advance drug development and cardiac regenerative medicine programs. Benefits include:
• KDR+/PDGFR-α+/c-Kit- human CPC marker profile
• bFGF-mediated proliferation
• WNT inhibitor-mediated differentiation into cTNT+ cardiomyocytes
• High-throughput target and phenotypic-based screen compatibility
Certain products are only available in select territories. Please contact your local Sales Representative or Product & Scientific Support at email@example.com for further information.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.